Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
You may also be interested in...
Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea
Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.
Korea’s Health Ministry Selects 43 Innovative Companies For Tax/Funding Benefits
Tax credits, priority for government projects and expanded funding opportunities will support 42 Korean firms and Korea-heavy Otsuka Pharmaceutical with R&D expansion
Pfizer’s Second Market For Targeted Lung Cancer Drug Xalkori Is Korea
After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.